Amylyx Pharmaceuticals Inc (NAS:AMLX)
$ 1.83 0 (0%) Market Cap: 124.45 Mil Enterprise Value: -245.15 Mil PE Ratio: 0 PB Ratio: 0.38 GF Score: 22/100

Amylyx Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 18, 2023 / 04:45PM GMT
Release Date Price: $30.82 (-0.10%)
Eason Lee
Needham & Co. - Analyst

Good afternoon, everyone. Welcome to our next session here with Amylyx. I'm Eason Lee, one of the associates on the biotech research team here at Needham. And it's my pleasure to be hosting Josh Cohen and Justin Klee, who are the co-CEOs and the co-founders as well as Jim Frates, who is the CFO of the company. We'll start off with a company presentation, followed by some time for Q&A.

Just as a reminder, for the listeners, if you have any questions that you'd like me to ask, please feel free to send it over through the chat function.

And with that, Josh, Justin, let me turn it over to you.

Justin Klee
Amylyx Pharmaceuticals Inc. - Co-CEO & Director

Thanks so much, Jason, for having us today and where we thank everyone for joining us as well. So, Josh and I are the cofounders of Amylyx and very pleased to take you through everything today, along with our colleague, Jim.

So, we're a company focused on neurodegenerative diseases in particular ALS. It really try to keep people living with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot